Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Viral Hepat ; 25(6): 649-660, 2018 06.
Artículo en Inglés | MEDLINE | ID: mdl-29316037

RESUMEN

Hepatitis C virus (HCV) chronically infects 2%-3% of the world's population, causing liver disease and cancer with prolonged infection. The narrow host range of the virus, being restricted largely to human hepatocytes, has made the development of relevant models to evaluate the efficacy of vaccines a challenge. We have developed a novel approach to accomplish this by generating a murine hepatoma cell line stably expressing nonstructural HCV antigens which can be used in vitro or in vivo to test HCV vaccine efficacies. These HCV-recombinant hepatoma cells formed large solid-mass tumours when implanted into syngeneic mice, allowing us to test candidate HCV vaccines to demonstrate the development of an HCV-specific immune response that limited tumour growth. Using this model, we tested the therapeutic potential of recombinant anti-HCV-specific vaccines based on two fundamentally different attenuated pathogen vaccine systems-attenuated Salmonella and recombinant adenoviral vector based vaccine. While attenuated Salmonella that secreted HCV antigens limited growth of the HCV-recombinant tumours when used in a therapeutic vaccination trial, replication-competent but noninfectious adenovirus expressing nonstructural HCV antigens showed overall greater survival and reduced weight loss compared to non-replicating nondisseminating adenovirus. Our results demonstrate a model with anti-tumour responses to HCV nonstructural (NS) protein antigens and suggest that recombinant vaccine vectors should be explored as a therapeutic strategy for controlling HCV and HCV-associated cancers.


Asunto(s)
Carcinoma Hepatocelular/patología , Modelos Animales de Enfermedad , Neoplasias Hepáticas/patología , Animales , Antígenos Virales/biosíntesis , Antígenos Virales/genética , Carcinoma Hepatocelular/terapia , Carcinoma Hepatocelular/virología , Femenino , Expresión Génica , Hepacivirus/genética , Hepatocitos/virología , Neoplasias Hepáticas/terapia , Neoplasias Hepáticas/virología , Ratones Endogámicos C57BL , Modelos Biológicos , Trasplante de Neoplasias , Resultado del Tratamiento , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/inmunología , Vacunas contra Hepatitis Viral/administración & dosificación , Vacunas contra Hepatitis Viral/inmunología , Proteínas no Estructurales Virales/biosíntesis , Proteínas no Estructurales Virales/genética
4.
J Nucl Med ; 21(2): 135-8, 1980 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-7356751

RESUMEN

A radiometric method, based on inhibition of 14CO2 release from bacterial metabolism of C-14-labeled glucose, was applied to test the susceptibility of urinary organisms to antibiotics. The testing was also carried out by the routine disc diffusion method after isolation of the organisms. Results of susceptibility to antibiotics could be obtained within 2 to 4 hr by the radiometric technique, compared with the 48 hr required for the disc method.


Asunto(s)
Antiinfecciosos Urinarios/farmacología , Pruebas de Sensibilidad Microbiana/métodos , Infecciones Urinarias/microbiología , Bacterias/efectos de los fármacos , Bacterias/metabolismo , Dióxido de Carbono/metabolismo , Radioisótopos de Carbono , Glucosa/metabolismo , Humanos , Factores de Tiempo , Infecciones Urinarias/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA